Desvenlafaxine
Desvenlafaxine, Pristiq (desvenlafaxine) is a small molecule pharmaceutical. Desvenlafaxine was first approved as Pristiq on 2008-02-29. It is used to treat major depressive disorder in the USA. The pharmaceutical is active against sodium-dependent noradrenaline transporter and sodium-dependent serotonin transporter. In addition, it is known to target sodium-dependent dopamine transporter.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
Desvenlafaxine, Pristiq (discontinued: Desvenlafaxine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Desvenlafaxine fumarate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DESVENLAFAXINE | Sun Pharmaceutical Industries | N-205583 DISCN | 2014-01-28 | 2 products, RLD |
| DESVENLAFAXINE | Teva | N-205208 DISCN | 2013-10-11 | 2 products |
Hide discontinued
Desvenlafaxine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DESVENLAFAXINE | Alembic Pharmaceuticals | N-204150 RX | 2013-03-04 | 2 products, RLD, RS |
Desvenlafaxine succinate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PRISTIQ | CV Sciences | N-021992 RX | 2008-02-29 | 3 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| desvenlafaxine | ANDA | 2025-09-18 |
| desvenlafaxine er | ANDA | 2025-05-12 |
| desvenlafaxine succinate | ANDA | 2025-03-13 |
| pristiq | New Drug Application | 2024-12-19 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| major depressive disorder | EFO_0003761 | D003865 | F22 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Desvenlafaxine Succinate, Pristiq, Pf Prism Cv | |||
| 8269040 | 2027-07-05 | DP | |
HCPCS
No data
Clinical
Clinical Trials
163 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 13 | 15 | 39 | 26 | 13 | 102 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 11 | 13 | 41 | 25 | 11 | 97 |
| Depression | D003863 | — | F33.9 | 6 | 15 | 40 | 29 | 9 | 95 |
| Healthy volunteers/patients | — | — | — | 9 | — | 1 | 1 | — | 11 |
| Hot flashes | D019584 | — | — | 2 | — | 3 | 2 | 2 | 9 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | 4 | 2 | 7 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | 1 | 2 | 1 | 1 | 2 | 6 |
| Dysthymic disorder | D019263 | EFO_0008623 | F34.1 | — | 1 | — | 2 | 2 | 5 |
| Generalized anxiety disorder | D000098647 | — | — | — | — | 1 | 2 | 2 | 5 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | 1 | 2 | 3 |
Show 18 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | 1 | 2 | — | — | 3 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | 1 | — | 2 | — | — | 3 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | 1 | — | 2 | 3 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | 2 | — | — | 2 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 2 | 1 | — | — | 2 |
| Peripheral nervous system diseases | D010523 | — | G64 | — | — | 2 | — | — | 2 |
| Sleep | D012890 | GO_0030431 | — | — | — | 1 | — | — | 1 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | 1 | — | — | 1 |
| Neoplasms | D009369 | — | C80 | — | 1 | 1 | — | — | 1 |
| Postpartum depression | D019052 | EFO_0007453 | F53.0 | — | — | 1 | — | — | 1 |
Show 3 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | 3 | — | — | — | 3 |
| Infections | D007239 | EFO_0000544 | — | — | 2 | — | — | — | 2 |
| Communicable diseases | D003141 | — | — | — | 2 | — | — | — | 2 |
| Respiratory syncytial virus infections | D018357 | EFO_1001413 | — | — | 2 | — | — | — | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | — | 1 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | 1 | — | — | — | 1 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | 1 | — | — | — | 1 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | — | N19 | — | — | — | — | 1 | 1 |
| Acute kidney injury | D058186 | — | N17 | — | — | — | — | 1 | 1 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | — | 1 | 1 |
| Panic disorder | D016584 | EFO_0004262 | F41.0 | — | — | — | — | 1 | 1 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | — | — | — | 1 | 1 |
| Cancer pain | D000072716 | — | G89.3 | — | — | — | — | 1 | 1 |
| Vomiting | D014839 | — | R11.1 | — | — | — | — | 1 | 1 |
| Nausea | D009325 | — | R11.0 | — | — | — | — | 1 | 1 |
| Adjustment disorders | D000275 | — | F43.2 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Desvenlafaxine |
| INN | desvenlafaxine |
| Description | O-desmethylvenlafaxine is a tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-hydroxyphenyl group. It is a metabolite of the drug venlafaxine. It has a role as a marine xenobiotic metabolite, a drug metabolite and an antidepressant. It is a member of cyclohexanols, a member of phenols and a tertiary amino compound. |
| Classification | Small molecule |
| Drug class | antianxiety, antidepressant inhibitor of norepinephrine and dopamine re-uptake |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1 |
Identifiers
| PDB | — |
| CAS-ID | 93413-62-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1118 |
| ChEBI ID | 83527 |
| PubChem CID | 125017 |
| DrugBank | DB06700 |
| UNII ID | NG99554ANW (ChemIDplus, GSRS) |
Target
Agency Approved
SLC6A2
SLC6A2
SLC6A4
SLC6A4
Organism
Homo sapiens
Gene name
SLC6A2
Gene synonyms
NAT1, NET1, SLC6A5
NCBI Gene ID
Protein name
sodium-dependent noradrenaline transporter
Protein synonyms
NET, neurotransmitter transporter, Norepinephrine transporter, solute carrier family 6 (neurotransmitter transporter), member 2, solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2, Solute carrier family 6 member 2, solute carrier family 6 member 5
Uniprot ID
Mouse ortholog
Slc6a2 (20538)
sodium-dependent noradrenaline transporter (Q6QU62)
Alternate
SLC6A3
SLC6A3
Organism
Homo sapiens
Gene name
SLC6A3
Gene synonyms
DAT1
NCBI Gene ID
Protein name
sodium-dependent dopamine transporter
Protein synonyms
DA transporter, dopamine transporter 1, solute carrier family 6 (neurotransmitter transporter), member 3, solute carrier family 6 (neurotransmitter transporter, dopamine), member 3, Solute carrier family 6 member 3
Uniprot ID
Mouse ortholog
Slc6a3 (13162)
sodium-dependent dopamine transporter (Q9R1I2)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Pristiq – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Desvenlafaxine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,854 documents
View more details
Safety
Black-box Warning
Black-box warning for: Desvenlafaxine, Desvenlafaxine er, Desvenlafaxine succinate, Pristiq
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
22,385 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use